- Home
- NXC vs CGTX Comparison
NXC vs CGTX Comparison
Compare NXC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXC | CGTX |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NXC | CGTX |
|---|---|---|
| Price | $13.19 | $1.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 17.5K | ★ 896.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.86 | $0.22 |
| 52 Week High | $13.70 | $3.83 |
Technical Indicators
Market Signals| Indicator | NXC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 46.72 |
| Support Level | $13.13 | $1.33 |
| Resistance Level | $13.24 | $1.62 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 51.16 | 32.56 |
Price Performance
Historical ComparisonAbout NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing in municipal obligations.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.